Menu
Thor Medical, a leading supplier of high-purity isotopes to the radiopharmaceutical industry, has entered into a three-year supply agreement with Medicines Discovery Catapult (MDC), a life science service dedicated to turning drug discovery into commercial breakthroughs.
Under the agreement, Thor Medical will supply radium-224 (Ra-224) and lead-212 (Pb-212) from its industrial-scale AlphaOne facility. The agreement will support MDC's wider work to accelerate the development of Pb-212- and Ra-224-based radiopharmaceutical therapies in the UK. First shipments to MDC have already been made.
“We are pleased to support Medicines Discovery Catapult with the isotopes it needs to help advance radiopharmaceutical development in the UK. Since opening AlphaOne, we are seeing increasing interest in securing predictable and stable isotope supply, which is an important enabler for preclinical development. We look forward to supporting MDC and the programmes it works with over the coming years,” said Jasper C. Kurth, CEO of Thor Medical.
With increasing investment in the development, manufacture, and clinical translation of precision radiopharmaceutical medicines, a reliable supply of medical isotopes remains fundamental to advancing research and development in this space.
Alongside securing isotope supplies for development programmes, MDC is supporting initiatives to strengthen the UK's future capability. This includes a £18.8 million consortium, partially funded by Innovate UK’s Sustainable Medicines Manufacturing Innovation Programme and led by United Kingdom National Nuclear Laboratory and Medicines Discovery Catapult, which is working to establish the ecosystem of a UK Pb-212 supply chain.
Together, these activities help ensure innovators can access the isotopes they need today while supporting the long-term growth of UK radiopharmaceutical capability.
“This agreement with Thor Medical strengthens MDC’s ability to support radiopharmaceutical developers in getting precision treatments closer to patients. By combining isotope supply with MDC’s preclinical development capabilities, we can help partners generate the evidence needed to progress programmes from early discovery to clinical development and future impact,” said Dr. Juliana Maynard, Chief Scientist, Translational Imaging and Radiopharmaceuticals, Medicines Discovery Catapult.
ENDS
For further information, please contact:
Thor Medical ASA
Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
+47 988 05 724
mathias.reierth@thormedical.com
Medicines Discovery Catapult
Georgia Hawkins
Senior Communications Manager
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit thormedical.com
ABOUT MEDICINES DISCOVERY CATAPULT
Medicines Discovery Catapult (MDC) is a Life Sciences service dedicated to turning drug discovery into commercial breakthroughs.
At the frontier of drug discovery, MDC works with entrepreneurial scientists to make every move count. It validates their ideas, de-risks investments, and feeds insights back into the sector to drive productivity and impact.
MDC creates momentum through its unique blend of discovery expertise, technology, insights, and sector-leading partnerships. Where there is unmet patient need, MDC stimulates innovation through its National Programmes.
MDC has worked with over 427 organisations, who have gone on to raise more than £2.2bn of R&D investment.
Its approach to drug discovery drives game-changing breakthroughs and improves patients’ lives.
More information:
